B-
BiotechTV - News
STIFEL 2026: Rapport Therapeutics' CEO Abe Ceesay highlights the company's recent phase 2 success for RAP-219 in bipolar mania and discusses the next steps ahead
0:00-8:09
He describes the company's precision mechanism, and discussions they will have with FDA before starting phase 3 trials in this indicuation next year. Plus, previewing long-term data that will be out soon in epilepsy.
Publisher
BiotechTV - News
Link
podcasters.spotify.com/pod/show/biotechtv4/episodes/STIFEL-2026-Rapport-Therapeutics-CEO-Abe-Ceesay-highlights-the-companys-recent-phase-2-success-for-RAP-219-in-bipolar-mania-and-discusses-the-next-steps-ahead-e3s7k8e
Published
November 11, 2026
Duration
8 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
BiotechTV
B-
BiotechTV - News
@biotechtvnews
#rapporttherapeuticsceo #companysrecentphase #bipolarmania #lifesciences
